Hookipa Pharma Inc (HOOK) Receives a Buy from RBC Capital

By Jason Carr

In a report issued on August 12, Brian Abrahams from RBC Capital maintained a Buy rating on Hookipa Pharma Inc (HOOKResearch Report), with a price target of $23. The company’s shares closed last Monday at $7, close to its 52-week low of $6.06.

According to TipRanks.com, Abrahams is a 4-star analyst with an average return of 4.8% and a 49.5% success rate. Abrahams covers the Healthcare sector, focusing on stocks such as Proteostasis Therapeutics Inc, Intra-Cellular Therapies, and Alder Biopharmaceuticals.

The the analyst consensus on Hookipa Pharma Inc is currently a Hold rating.

See today’s analyst top recommended stocks >>

Based on Hookipa Pharma Inc’s latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $9.33 million. In comparison, last year the company had a GAAP net loss of $4.57 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

HOOKIPA Pharma, Inc. engages in the development of immunotherapeutics, targeting infectious diseases and cancers based on its proprietary its arenavirus platform that is designed to reprogram the body’s immune system.